Open AccessEfficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis
Author(s) -
Timothy Felton,
Caroline Baxter,
Caroline B. Moore,
Stephen A. Roberts,
William Hope,
David W. Denning
Publication year - 2010
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/657306
Subject(s) - posaconazole , medicine , rash , aspergillosis , mycosis , gastroenterology , surgery , voriconazole , immunology , dermatology , antifungal
Chronic pulmonary aspergillosis (CPA) is a severe, progressive respiratory infection characterized by multiple pulmonary cavities and increased levels of antibodies to Aspergillus species. We report the first use of posaconazole in patients with CPA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom